AU2014253785B2 - Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones - Google Patents

Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones Download PDF

Info

Publication number
AU2014253785B2
AU2014253785B2 AU2014253785A AU2014253785A AU2014253785B2 AU 2014253785 B2 AU2014253785 B2 AU 2014253785B2 AU 2014253785 A AU2014253785 A AU 2014253785A AU 2014253785 A AU2014253785 A AU 2014253785A AU 2014253785 B2 AU2014253785 B2 AU 2014253785B2
Authority
AU
Australia
Prior art keywords
ala
leu
lys
val
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014253785A
Other languages
English (en)
Other versions
AU2014253785A1 (en
Inventor
Dan Groff
Patrick RIVERS
Christopher D. Thanos
Alice Yam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sutro Biopharma Inc
Original Assignee
Sutro Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sutro Biopharma Inc filed Critical Sutro Biopharma Inc
Publication of AU2014253785A1 publication Critical patent/AU2014253785A1/en
Application granted granted Critical
Publication of AU2014253785B2 publication Critical patent/AU2014253785B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2014253785A 2013-04-19 2014-04-18 Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones Active AU2014253785B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361813914P 2013-04-19 2013-04-19
US61/813,914 2013-04-19
US201461937069P 2014-02-07 2014-02-07
US61/937,069 2014-02-07
PCT/US2014/034643 WO2014172631A2 (en) 2013-04-19 2014-04-18 Expression of biologically active proteins in a bacterial cell-free synthesis system using bacterial cells transformed to exhibit elevated levels of chaperone expression

Publications (2)

Publication Number Publication Date
AU2014253785A1 AU2014253785A1 (en) 2015-11-05
AU2014253785B2 true AU2014253785B2 (en) 2018-07-19

Family

ID=50733442

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014253785A Active AU2014253785B2 (en) 2013-04-19 2014-04-18 Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones

Country Status (13)

Country Link
US (3) US10190145B2 (enExample)
EP (1) EP2986731B1 (enExample)
JP (2) JP6463732B2 (enExample)
KR (1) KR102289258B1 (enExample)
CN (1) CN105283556B (enExample)
AU (1) AU2014253785B2 (enExample)
CA (1) CA2909516C (enExample)
DK (1) DK2986731T3 (enExample)
ES (1) ES2922358T3 (enExample)
HU (1) HUE059565T2 (enExample)
IL (1) IL242148B (enExample)
SG (2) SG11201508642WA (enExample)
WO (1) WO2014172631A2 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014253785B2 (en) 2013-04-19 2018-07-19 Sutro Biopharma, Inc. Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones
US10316322B2 (en) * 2014-07-02 2019-06-11 Sutro Biopharma, Inc. High growth capacity auxotrophic Escherichia coli and methods of use
HRP20201351T1 (hr) * 2014-11-05 2020-11-27 Genentech, Inc. Postupci proizvodnje dvolančanih proteina u bakteriji
AU2015342961B2 (en) 2014-11-05 2021-08-12 Genentech, Inc. Methods of producing two chain proteins in bacteria
US10487133B2 (en) 2014-12-19 2019-11-26 Sutro Biopharma, Inc. Codon optimization for titer and fidelity improvement
WO2016109415A1 (en) 2014-12-30 2016-07-07 Celgene Corporation Anti-cd47 antibodies and uses thereof
SG10202005917SA (en) * 2015-03-06 2020-07-29 Genentech Inc Ultrapurified dsba and dsbc and methods of making and using the same
US20170029798A1 (en) * 2015-07-27 2017-02-02 Cellivery Therapeutics, Inc. Development of Improved Cell-Permeable (iCP) Parkin Recombinant Protein as a Protein-Based Anti-Neurodegenerative Agent for the Treatment of Parkinson's Disease-Associated Phenotypes by Utilizing BBB-Penetrating Protein Delivery System MITT, Enabled by Advanced Macromolecule Transduction Domain (aMTD)
EP3337819B1 (en) * 2015-08-20 2024-02-21 F. Hoffmann-La Roche AG Method of purifying for producing recombinant polypeptides using fkpa
CN105198983B (zh) * 2015-09-11 2018-11-06 中国石油大学(华东) 一种利于七次跨膜蛋白ccr5功能性表达的方法
CN106190940B (zh) * 2016-07-19 2019-06-14 北京三元基因药业股份有限公司 表达抗TNF抗体Fab片段的重组大肠杆菌工程菌
CN106399352B (zh) * 2016-11-09 2020-04-17 华东理工大学 调节目标蛋白表达的折叠因子及其应用
MX2019007910A (es) 2016-12-30 2019-12-05 Sutrovax Inc Conjugados de polipeptido-antigeno con aminoacidos no naturales.
US12227778B2 (en) 2016-12-30 2025-02-18 Nature's Toolbox, Inc. Cell-free expression system having novel inorganic polyphosphate-based energy regeneration
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
WO2018126287A1 (en) 2016-12-30 2018-07-05 Ntxbio, Llc Cell-free expression system having novel inorganic polyphosphate-based energy regeneration
SG11202000167SA (en) 2017-07-11 2020-02-27 Synthorx Inc Incorporation of unnatural nucleotides and methods thereof
JP7097438B2 (ja) 2017-07-11 2022-07-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
KR20250145137A (ko) 2017-08-03 2025-10-13 신톡스, 인크. 자가면역 질환의 치료를 위한 사이토카인 접합체
EP3665188A4 (en) * 2017-08-11 2021-07-21 Synvitrobio, Inc. IMPROVED IN VITRO TRANSLATION / TRANSLATION SYSTEM (TXTL) AND ITS USES
WO2019127469A1 (zh) * 2017-12-29 2019-07-04 康码（上海）生物科技有限公司 一种高效的能源再生体系(bes)、试剂盒及其制备方法
WO2019165453A1 (en) 2018-02-26 2019-08-29 Synthorx, Inc. Il-15 conjugates and uses thereof
JP7340591B2 (ja) 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
KR20210090645A (ko) 2018-11-05 2021-07-20 제넨테크, 인크. 원핵 숙주 세포에서 2개의 사슬 단백질을 생산하는 방법
IL282875B2 (en) * 2018-11-08 2026-05-01 Sutro Biopharma Inc E. coli strains with oxygenated cytoplasm
BR112021005401A2 (pt) 2018-11-08 2021-06-29 Synthorx, Inc. conjugados de interleucina 10 e usos dos mesmos
CN109371049A (zh) * 2018-11-14 2019-02-22 天津大学 分子伴侣在促进单克隆抗体的形成和/或提高单克隆抗体的表达量中的应用
US20200246467A1 (en) 2019-02-06 2020-08-06 Synthorx, Inc. Il-2 conjugates and methods of use thereof
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
WO2021178001A1 (en) * 2020-03-05 2021-09-10 Curie Co. Inc. Methods for cell free protein expression of mature polypeptides derived from zymogens and proproteins
TW202543680A (zh) 2019-08-15 2025-11-16 美商欣爍克斯公司 使用il-2接合物之免疫腫瘤學組合療法
MX2022002740A (es) 2019-09-10 2022-03-25 Synthorx Inc Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
AU2020380275A1 (en) 2019-11-04 2022-04-14 Synthorx, Inc. Interleukin 10 conjugates and uses thereof
EP4056584A4 (en) * 2019-11-08 2024-06-05 Korea Institute of Ocean Science & Technology NOVEL HUMAN EPIDERMAL GROWTH FACTOR-TF FUSION PROTEIN AND USE THEREOF
EP4142711A1 (en) * 2020-04-29 2023-03-08 Willow Biosciences Inc. Compositions and methods for enhancing recombinant biosynthesis of cannabinoids
JP2023531509A (ja) 2020-06-25 2023-07-24 シンソークス， インコーポレイテッド Ｉｌ－２コンジュゲートおよび抗ｅｇｆｒ抗体を用いる免疫腫瘍学併用療法
KR20220000028U (ko) 2020-06-29 2022-01-05 채인자 농작물용 농약 간편 분무장치
JP2023544254A (ja) * 2020-09-14 2023-10-23 ストロ バイオファーマ， インコーポレイテッド 無細胞タンパク質合成系を用いた抗体の大規模産生方法
IL301611A (en) 2020-10-09 2023-05-01 Synthorx Inc Immuno oncology combination therapy with il-2 conjugates and pembrolizumab
JP2023546010A (ja) 2020-10-09 2023-11-01 シンソークス， インコーポレイテッド Ｉｌ－２コンジュゲートを用いた免疫腫瘍療法
TW202245843A (zh) 2021-02-12 2022-12-01 美商欣爍克斯公司 Ｉｌ－２接合物及西米普利單抗（ｃｅｍｉｐｌｉｍａｂ）之皮膚癌組合療法
TW202302148A (zh) 2021-02-12 2023-01-16 美商欣爍克斯公司 使用ｉｌ－２接合物和抗ｐｄ－１抗體或其抗原結合片段的肺癌組合療法
TW202313679A (zh) 2021-06-03 2023-04-01 美商欣爍克斯公司 包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法
WO2023122573A1 (en) 2021-12-20 2023-06-29 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2023122750A1 (en) 2021-12-23 2023-06-29 Synthorx, Inc. Cancer combination therapy with il-2 conjugates and cetuximab
CN116555061A (zh) * 2022-01-28 2023-08-08 北京师范大学 一种酿酒酵母突变体及其在制备酒精中的应用
CA3255881A1 (en) * 2022-06-17 2023-12-21 Insitro, Inc. In situ sequencing of RNA transcripts with non-uniform 5' ends
CN115028691B (zh) * 2022-06-29 2024-09-10 青岛硕景生物科技有限公司 一种检测试纸用的独立质控系统、杂交瘤细胞株、质控线用包被单克隆抗体及其应用
WO2024136899A1 (en) 2022-12-21 2024-06-27 Synthorx, Inc. Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
TW202444349A (zh) 2023-03-20 2024-11-16 美商欣爍克斯公司 使用ｉｌ－２綴合物之癌症療法
CN116925196B (zh) * 2023-06-08 2025-04-18 齐鲁工业大学(山东省科学院) 小分子热休克蛋白rsp_1572在提高宿主菌环境耐受性中的应用
WO2025158385A1 (en) 2024-01-25 2025-07-31 Genzyme Corporation Pegylated il-2 for suppressing adaptive immune response to gene therapy
CN118048325B (zh) * 2024-04-16 2024-07-16 天津凯莱英生物科技有限公司 酶的高通量筛选方法及酶库的构建方法
WO2025218039A1 (zh) * 2024-04-16 2025-10-23 天津凯莱英生物科技有限公司 酶的高通量筛选方法及酶库的构建方法
WO2025240255A1 (en) * 2024-05-11 2025-11-20 Biodiscovery, Llc Systems and methods of cell-free protein expression

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003025116A2 (de) * 2001-09-17 2003-03-27 Roche Diagnostics Gmbh Verfahren zur erhöhung der löslichkeit, der expressionsrate und der aktivität von proteinen während der rekombinanten herstellung
WO2008066583A2 (en) * 2006-06-29 2008-06-05 The Board Of Trustees Of The Leland Stanford Junior University Cell-free synthesis of proteins containing unnatural amino acids
US7871794B2 (en) * 2007-01-18 2011-01-18 The Board Of Trustees Of The Leland Stanford Junior University Enhanced cell-free synthesis of active proteins containing disulfide bonds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004081033A2 (en) * 2003-03-11 2004-09-23 National Institutes Of Health Synthesis of proteins by cell-free protein expression
JP2005253432A (ja) * 2004-03-15 2005-09-22 Sekisui Chem Co Ltd タンパク質の生産方法、並びにそれに使用するための組成物、試薬及びキット
JP4561243B2 (ja) * 2004-08-27 2010-10-13 株式会社豊田中央研究所 無細胞タンパク質合成系のための媒体
EP2376647B1 (en) * 2009-01-12 2014-03-05 Sutro Biopharma, Inc. Mono charging system for selectively introducing non-native amino acids into proteins using an in vitro protein synthesis system
US20110136169A1 (en) * 2009-11-20 2011-06-09 Rutgers, The State University Of New Jersey Expression system compositions and methods
CN102732548A (zh) 2012-05-16 2012-10-17 中国农业大学 一种表达蛇毒激肽原酶的高效麦胚无细胞蛋白合成系统的建立及应用
AU2013329464C1 (en) * 2012-10-12 2018-02-15 Sutro Biopharma, Inc. Proteolytic inactivation of select proteins in bacterial extracts for improved expression
AU2014253785B2 (en) * 2013-04-19 2018-07-19 Sutro Biopharma, Inc. Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003025116A2 (de) * 2001-09-17 2003-03-27 Roche Diagnostics Gmbh Verfahren zur erhöhung der löslichkeit, der expressionsrate und der aktivität von proteinen während der rekombinanten herstellung
WO2008066583A2 (en) * 2006-06-29 2008-06-05 The Board Of Trustees Of The Leland Stanford Junior University Cell-free synthesis of proteins containing unnatural amino acids
US7871794B2 (en) * 2007-01-18 2011-01-18 The Board Of Trustees Of The Leland Stanford Junior University Enhanced cell-free synthesis of active proteins containing disulfide bonds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KANG, S.-H. ET AL., "Cell-Free Production of Aggregation-Prone Proteins in Soluble and Active Forms", BIOTECHNOLOGY PROGRESS, (2005), vol. 21, no. 4, pages 1412 - 1419 *
OH, I.-S. ET AL., "Cell-free production of functional antibody fragments", BIOPROCESS AND BIOSYSTEMS ENGINEERING, (2009), vol. 33, no. 1 *
OH, I.-S. ET AL., BIOTECHNOLOGY PROGRESS, (2006), vol. 22, no. 4, pages 1225 -1228 *
XU, Y. ET AL., "Effect of folding factors in rescuing unstable heterologous lipase B to enhance its overexpression in the periplasm of Escherichia coli", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, (2008), vol. 79, no. 6, pages 1035 -1044 *

Also Published As

Publication number Publication date
CA2909516C (en) 2023-03-07
DK2986731T3 (da) 2022-08-01
US10190145B2 (en) 2019-01-29
JP2018157837A (ja) 2018-10-11
WO2014172631A3 (en) 2014-12-18
US10774354B2 (en) 2020-09-15
KR102289258B1 (ko) 2021-08-11
HK1220993A1 (en) 2017-05-19
SG10202108497TA (en) 2021-09-29
US20210054429A1 (en) 2021-02-25
AU2014253785A1 (en) 2015-11-05
ES2922358T3 (es) 2022-09-13
HUE059565T2 (hu) 2022-11-28
EP2986731A2 (en) 2016-02-24
JP6463732B2 (ja) 2019-02-06
JP2016518833A (ja) 2016-06-30
US20190161781A1 (en) 2019-05-30
CN105283556B (zh) 2020-07-14
WO2014172631A4 (en) 2015-02-19
IL242148B (en) 2019-03-31
CA2909516A1 (en) 2014-10-23
US20140315245A1 (en) 2014-10-23
WO2014172631A2 (en) 2014-10-23
EP2986731B1 (en) 2022-05-18
SG11201508642WA (en) 2015-11-27
KR20160002913A (ko) 2016-01-08
CN105283556A (zh) 2016-01-27

Similar Documents

Publication Publication Date Title
US10774354B2 (en) Expression of biologically active proteins in a bacterial cell-free synthesis system using bacterial cells transformed to exhibit elevated levels of chaperone expression
US10487133B2 (en) Codon optimization for titer and fidelity improvement
CN101479379B (zh) 含有非天然氨基酸的蛋白质的无细胞合成
US7871794B2 (en) Enhanced cell-free synthesis of active proteins containing disulfide bonds
US20200332280A1 (en) Use of lambda-gam protein in ribosomal display technology
TWI899326B (zh) 使用無細胞蛋白質合成系統來大規模生產抗體之方法
HK1220993B (en) Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones
WO2005105994A1 (ja) ジスルフィド架橋形成型インビトロタンパク質合成方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)